NASDAQ:ATRA Atara Biotherapeutics Q1 2025 Earnings Report $8.54 -0.02 (-0.23%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Atara Biotherapeutics EPS ResultsActual EPS$3.50Consensus EPS -$3.07Beat/MissBeat by +$6.57One Year Ago EPSN/AAtara Biotherapeutics Revenue ResultsActual Revenue$98.10 millionExpected Revenue$4.30 millionBeat/MissBeat by +$93.80 millionYoY Revenue GrowthN/AAtara Biotherapeutics Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateThursday, May 15, 2025Conference Call Time8:30AM ETUpcoming EarningsAtara Biotherapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Atara Biotherapeutics Earnings HeadlinesAtara Biotherapeutics (NASDAQ:ATRA) Share Price Passes Below Fifty Day Moving Average - Time to Sell?September 23 at 4:21 AM | americanbankingnews.comAtara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational ProgressAugust 12, 2026 | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 24 at 1:00 AM | Decentralized Masters (Ad)Atara Biotherapeutics Announces $15 Million Registered Direct OfferingJuly 7, 2026 | businesswire.comQuetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic LeukemiaJune 11, 2026 | globenewswire.comAtara Biotherapeutics Inc (ATRA)May 31, 2026 | investing.comSee More Atara Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email. Email Address About Atara BiotherapeuticsAtara Biotherapeutics (NASDAQ:ATRA) is a biotechnology company focused on developing allogeneic T-cell immunotherapies for cancer, autoimmune diseases and other serious conditions. Its platform uses T cells derived from healthy donors and engineered or selected to recognize disease-associated targets, with the goal of creating “off-the-shelf” treatments that can be administered without collecting and manufacturing a patient’s own cells. The company’s leading product is tabelecleucel, marketed as Ebvallo, an allogeneic T-cell therapy designed to target Epstein-Barr virus-positive cells. Ebvallo has been approved in the United States and European Union for certain patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a rare and potentially life-threatening complication that can occur after organ or stem-cell transplantation. Atara has also investigated its platform in multiple sclerosis and other immune-mediated diseases, as well as additional oncology indications. Founded in 2012, Atara has operated internationally through clinical development, regulatory and commercial activities in North America and Europe. The company has collaborated with external partners to support the development, manufacturing and commercialization of its therapies. Pascal Touchon has served as Atara’s president and chief executive officer, although leadership and corporate arrangements may change as the company’s business develops.View Atara Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
